voriconazol al 200 mg pulver zur herstellung einer infusionslösung
voriconazole hikma (previously voriconazole hospira)
hikma farmaceutica (portugal) s.a. - voriconazole - bacterial infections and mycoses; aspergillosis; candidiasis - antimycotics for systemic use - voriconazole is a broad spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows:treatment of invasive aspergillosis;treatment of candidaemia in non-neutropenic patients;treatment of fluconazole-resistant serious invasive candida infections (including c. krusei);treatment of serious fungal infections caused by scedosporium spp. and fusarium spp.voriconazole should be administered primarily to patients with progressive, possibly life-threatening infections.prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (hsct)recipients.
prevymis 240mg/12ml (20mg/ml) concentrate for solution for infusion
merck sharp & dohme (malaysia) sdn bhd - letermovir -
prevymis 480mg/24ml (20mg/ml) concentrate for solution for infusion
merck sharp & dohme (malaysia) sdn bhd - letermovir -
posaconazol altan 300 mg konzentrat zur herstellung einer infusionslösung
baxdela- delafloxacin meglumine tablet baxdela- delafloxacin meglumine injection, powder, lyophilized, for solution
melinta therapeutics, llc - delafloxacin meglumine (unii: n7v53u4u4t) (delafloxacin - unii:6315412yvf) - delafloxacin 450 mg - baxdela is indicated in adults for the treatment of acute bacterial skin and skin structure infections (absssi) caused by the following susceptible microorganisms: staphylococcus aureus (including methicillin-resistant [mrsa] and methicillin-susceptible [mssa] isolates), staphylococcus haemolyticus, staphylococcus lugdunensis, streptococcus agalactiae , streptococcus anginosus group (including streptococcus anginosus , streptococcus intermedius , and streptococcus constellatus ), streptococcus pyogenes , enterococcus faecalis , escherichia coli, enterobacter cloacae, klebsiella pneumoniae, and pseudomonas aeruginosa. baxdela is indicated in adults for the treatment of community-acquired bacterial pneumonia (cabp) caused by the following susceptible microorganisms: streptococcus pneumoniae, staphylococcus aureus (methicillin-susceptible [mssa] isolates only), klebsiella pneumoniae , escherichia coli, pseudomonas aeruginosa, haemophilus influenzae, haemophilus parainfluenzae , chlamydia pneumoniae , legione
veklury
gilead sciences ireland uc - remdesivir - covid-19 virus infection - veklury is indicated for the treatment of coronavirus disease 2019 (covid 19) in:adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19
posaconazol accord 300 mg konzentrat zur herstellung einer infusionslösung
viagra odt (orodispersible ) tablet 50mg
viatris private limited - sildenafil citrate 70.225mg eqv. sildenafil - tablet, orally disintegrating - 50mg - sildenafil citrate 70.225mg eqv. sildenafil 50mg
extraneal
vantive limited - calcium chloride dihydrate 257 mg/l; icodextrin 75 g/l; magnesium chloride hexahydrate 51 mg/l; sodium chloride 5.4 g/l; sodium lactate 4.5 g/l - dialysis solution - 7.5% w/v - active: calcium chloride dihydrate 257 mg/l icodextrin 75 g/l magnesium chloride hexahydrate 51 mg/l sodium chloride 5.4 g/l sodium lactate 4.5 g/l excipient: hydrochloric acid sodium hydroxide water for injection